published meta-analysis   sensitivity analysis   studies

miscellaneous in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable recoverydetailed resultsCrippa (CANDIDATE), 2021 0.54 [0.15; 1.94] 0.54[0.15; 1.94]Crippa (CANDIDATE), 202110%91NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-18 12:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924 - roots T: 290